DexCom, Inc. (NASDAQ:DXCM) Receives $97.42 Consensus PT from Analysts

DexCom, Inc. (NASDAQ:DXCM) has received an average recommendation of “Moderate Buy” from the twenty-three brokerages that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $97.4211.

Several equities research analysts have recently weighed in on DXCM shares. Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. UBS Group increased their price objective on shares of DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Mizuho increased their price objective on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Raymond James Financial increased their price objective on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 31st. Finally, William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,849 shares of company stock valued at $564,733. Company insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On DexCom

Large investors have recently bought and sold shares of the stock. SWS Partners acquired a new stake in DexCom in the second quarter worth $1,661,000. Baader Bank Aktiengesellschaft bought a new position in shares of DexCom in the second quarter valued at $393,000. Assenagon Asset Management S.A. lifted its stake in shares of DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after buying an additional 557,576 shares in the last quarter. Mn Services Vermogensbeheer B.V. lifted its stake in shares of DexCom by 4.9% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after buying an additional 6,800 shares in the last quarter. Finally, Shell Asset Management Co. lifted its stake in shares of DexCom by 16.8% in the second quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock valued at $3,126,000 after buying an additional 5,138 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Trading Down 4.3%

Shares of NASDAQ DXCM opened at $65.12 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom has a 52-week low of $57.52 and a 52-week high of $93.25. The firm has a 50 day moving average price of $74.42 and a two-hundred day moving average price of $77.72. The stock has a market cap of $25.54 billion, a P/E ratio of 45.22, a price-to-earnings-growth ratio of 1.37 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the company posted $0.43 EPS. The company’s revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that DexCom will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.